



For immediate release, March 28, 2011

AGM postponed and the January-March Interim Report rescheduled

The Board of Directors of Genovis AB has decided to postpone the planned Annual General Meeting from April 28 until June 9, 2011. The reason for the delay is that the AGM cannot be held during an ongoing rights issue.

In addition, the Board decided to reschedule the January-March Interim Report for April 18 because all financial information must be disclosed before completion of the rights issue.

For more information, contact:
Sarah Fredriksson, CEO, Genovis AB
+46-46-10 12 35
sarah.fredriksson@genovis.com

Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company's patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission is our certified advisor.